PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer

Purpose [ 68 Ga]Tris(hydroxypyridinone)(THP)-PSMA is a novel radiopharmaceutical for one-step kit-based radiolabelling, based on direct chelation of 68 Ga 3+ at low concentration, room temperature and over a wide pH range, using direct elution from a 68 Ge/ 68 Ga-generator. We evaluated the clinical...

Full description

Saved in:
Bibliographic Details
Published in:European journal of nuclear medicine and molecular imaging 2018-06, Vol.45 (6), p.913-922
Main Authors: Derlin, Thorsten, Schmuck, Sebastian, Juhl, Cathleen, Zörgiebel, Johanna, Schneefeld, Sophie M., Walte, Almut C. A., Hueper, Katja, von Klot, Christoph A., Henkenberens, Christoph, Christiansen, Hans, Thackeray, James T., Ross, Tobias L., Bengel, Frank M.
Format: Article
Language:English
Subjects:
Biochemistry
Cancer surgery
Cardiology
Chelation
Computed tomography
Deprivation
Elution
Image detection
Imaging
Ligands
Medicine
Medicine & Public Health
Metastases
Nuclear Medicine
Oncology
Original Article
Orthopedics
Patients
pH effects
Pharmaceuticals
Positron emission
Prostate cancer
Prostatectomy
Radiochemical analysis
Radioisotopes
Radiolabelling
Radiology
Therapy
Tomography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c1949-828d6716c5dd32b40777009e86e5dfaeb56fe2bae8a269fdff404d60bf4a13b23
cites cdi_FETCH-LOGICAL-c1949-828d6716c5dd32b40777009e86e5dfaeb56fe2bae8a269fdff404d60bf4a13b23
container_end_page 922
container_issue 6
container_start_page 913
container_title European journal of nuclear medicine and molecular imaging
container_volume 45
creator Derlin, Thorsten
Schmuck, Sebastian
Juhl, Cathleen
Zörgiebel, Johanna
Schneefeld, Sophie M.
Walte, Almut C. A.
Hueper, Katja
von Klot, Christoph A.
Henkenberens, Christoph
Christiansen, Hans
Thackeray, James T.
Ross, Tobias L.
Bengel, Frank M.
description Purpose [ 68 Ga]Tris(hydroxypyridinone)(THP)-PSMA is a novel radiopharmaceutical for one-step kit-based radiolabelling, based on direct chelation of 68 Ga 3+ at low concentration, room temperature and over a wide pH range, using direct elution from a 68 Ge/ 68 Ga-generator. We evaluated the clinical detection rates of [ 68 Ga]THP-PSMA PET/CT in patients with biochemically recurrent prostate cancer after prostatectomy. Methods Consecutive patients (n=99) referred for evaluation of biochemical relapse of prostate cancer by [ 68 Ga]THP-PSMA PET/CT were analyzed retrospectively. Patients underwent a standard whole-body PET/CT (1 h p.i.), followed by delayed (3 h p.i.) imaging of the abdomen. PSA-stratified cohorts of positive PET/CT results, standardized uptake values (SUVs) and target-to-background ratios (TBRs) were analyzed, and compared between standard and delayed imaging. Results At least one lesion suggestive of recurrent or metastatic prostate cancer was identified on PET images in 52 patients (52.5%). Detection rates of [ 68 Ga]THP-PSMA PET/CT increased with increasing PSA level: 94.1% for a PSA value of ≥10 ng/mL, 77.3% for a PSA value of 2 to
doi_str_mv 10.1007/s00259-017-3924-9
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1989549167</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1989549167</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1949-828d6716c5dd32b40777009e86e5dfaeb56fe2bae8a269fdff404d60bf4a13b23</originalsourceid><addsrcrecordid>eNp1kV9rFDEUxQdRsLZ-AN8u-OJDo8nsTDJ5XEr_CBUXun0qMmSSm93U2cyaZJV-QL-Xd7tFpOBT_vA799zDqap3gn8UnKtPmfO61YwLxWa6bph-UR0JKTRTvNMv_94Vf129yfmec9HVnT6qfi9u5iyXZErwAR04LGhLmCLQF2bwU4I72V2ab8urBVvcfJmfgoE4_cQRtmka8JFIZhscfA-FDSbTlL2AjWbAMcQVmOhgcb6EsDErep9CiLAlQ4wlw69Q1jCEya5xE6wZIaHdpYTRIhhfMJENCdMDlDWSz8OjIVnnQguCNQSmk-qVN2PGt0_ncXV7cb48u2LXXy8_n82vmRW60YwiO6mEtK1zs3pouFKKc42dxNZ5g0MrPdaDwc7UUnvnfcMbJ_ngGyNmQz07rj4c5pL_jx3m0m9CtjiOJuK0y73QnW4bLaQi9P0z9H7apUjb7am2VbJtJFHiQFkKlBP6_iltL3i_L7Y_FNtTsf2-2F6Tpj5oMrFxhemfyf8V_QFaT6fR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1985576546</pqid></control><display><type>article</type><title>PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer</title><source>Springer Nature</source><creator>Derlin, Thorsten ; Schmuck, Sebastian ; Juhl, Cathleen ; Zörgiebel, Johanna ; Schneefeld, Sophie M. ; Walte, Almut C. A. ; Hueper, Katja ; von Klot, Christoph A. ; Henkenberens, Christoph ; Christiansen, Hans ; Thackeray, James T. ; Ross, Tobias L. ; Bengel, Frank M.</creator><creatorcontrib>Derlin, Thorsten ; Schmuck, Sebastian ; Juhl, Cathleen ; Zörgiebel, Johanna ; Schneefeld, Sophie M. ; Walte, Almut C. A. ; Hueper, Katja ; von Klot, Christoph A. ; Henkenberens, Christoph ; Christiansen, Hans ; Thackeray, James T. ; Ross, Tobias L. ; Bengel, Frank M.</creatorcontrib><description>Purpose [ 68 Ga]Tris(hydroxypyridinone)(THP)-PSMA is a novel radiopharmaceutical for one-step kit-based radiolabelling, based on direct chelation of 68 Ga 3+ at low concentration, room temperature and over a wide pH range, using direct elution from a 68 Ge/ 68 Ga-generator. We evaluated the clinical detection rates of [ 68 Ga]THP-PSMA PET/CT in patients with biochemically recurrent prostate cancer after prostatectomy. Methods Consecutive patients (n=99) referred for evaluation of biochemical relapse of prostate cancer by [ 68 Ga]THP-PSMA PET/CT were analyzed retrospectively. Patients underwent a standard whole-body PET/CT (1 h p.i.), followed by delayed (3 h p.i.) imaging of the abdomen. PSA-stratified cohorts of positive PET/CT results, standardized uptake values (SUVs) and target-to-background ratios (TBRs) were analyzed, and compared between standard and delayed imaging. Results At least one lesion suggestive of recurrent or metastatic prostate cancer was identified on PET images in 52 patients (52.5%). Detection rates of [ 68 Ga]THP-PSMA PET/CT increased with increasing PSA level: 94.1% for a PSA value of ≥10 ng/mL, 77.3% for a PSA value of 2 to &lt;10 ng/mL, 54.5% for a PSA value of 1 to &lt;2 ng/mL, 14.3% for a PSA value of 0.5 to &lt;1 ng/mL, 20.0% for a PSA value of &gt;0.2 to &lt;0.5, and 22.2% for a PSA value of 0.01 to 0.2 ng/mL. [ 68 Ga]THP-PSMA uptake (SUVs) in metastases decreased over time, whereas TBRs improved. Delayed imaging at 3 h p.i. exclusively identified pathologic findings in 2% of [ 68 Ga]THP-PSMA PET/CT scans. Detection rate was higher in patients with a Gleason score ≥8 ( P =0.02) and in patients receiving androgen deprivation therapy ( P =0.003). Conclusions In this study, [ 68 Ga]THP-PSMA PET/CT showed suitable detection rates in patients with biochemical recurrence of prostate cancer and PSA levels ≥ 2 ng /mL. Detections rates were lower than in previous studies evaluating other PSMA ligands, though prospective direct radiotracer comparison studies are mandatory particularly in patients with low PSA levels to evaluate the relative performance of different PSMA ligands.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-017-3924-9</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Biochemistry ; Cancer surgery ; Cardiology ; Chelation ; Computed tomography ; Deprivation ; Elution ; Image detection ; Imaging ; Ligands ; Medicine ; Medicine &amp; Public Health ; Metastases ; Nuclear Medicine ; Oncology ; Original Article ; Orthopedics ; Patients ; pH effects ; Pharmaceuticals ; Positron emission ; Prostate cancer ; Prostatectomy ; Radiochemical analysis ; Radioisotopes ; Radiolabelling ; Radiology ; Therapy ; Tomography</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2018-06, Vol.45 (6), p.913-922</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2018</rights><rights>European Journal of Nuclear Medicine and Molecular Imaging is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1949-828d6716c5dd32b40777009e86e5dfaeb56fe2bae8a269fdff404d60bf4a13b23</citedby><cites>FETCH-LOGICAL-c1949-828d6716c5dd32b40777009e86e5dfaeb56fe2bae8a269fdff404d60bf4a13b23</cites><orcidid>0000-0002-8786-4105</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids></links><search><creatorcontrib>Derlin, Thorsten</creatorcontrib><creatorcontrib>Schmuck, Sebastian</creatorcontrib><creatorcontrib>Juhl, Cathleen</creatorcontrib><creatorcontrib>Zörgiebel, Johanna</creatorcontrib><creatorcontrib>Schneefeld, Sophie M.</creatorcontrib><creatorcontrib>Walte, Almut C. A.</creatorcontrib><creatorcontrib>Hueper, Katja</creatorcontrib><creatorcontrib>von Klot, Christoph A.</creatorcontrib><creatorcontrib>Henkenberens, Christoph</creatorcontrib><creatorcontrib>Christiansen, Hans</creatorcontrib><creatorcontrib>Thackeray, James T.</creatorcontrib><creatorcontrib>Ross, Tobias L.</creatorcontrib><creatorcontrib>Bengel, Frank M.</creatorcontrib><title>PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose [ 68 Ga]Tris(hydroxypyridinone)(THP)-PSMA is a novel radiopharmaceutical for one-step kit-based radiolabelling, based on direct chelation of 68 Ga 3+ at low concentration, room temperature and over a wide pH range, using direct elution from a 68 Ge/ 68 Ga-generator. We evaluated the clinical detection rates of [ 68 Ga]THP-PSMA PET/CT in patients with biochemically recurrent prostate cancer after prostatectomy. Methods Consecutive patients (n=99) referred for evaluation of biochemical relapse of prostate cancer by [ 68 Ga]THP-PSMA PET/CT were analyzed retrospectively. Patients underwent a standard whole-body PET/CT (1 h p.i.), followed by delayed (3 h p.i.) imaging of the abdomen. PSA-stratified cohorts of positive PET/CT results, standardized uptake values (SUVs) and target-to-background ratios (TBRs) were analyzed, and compared between standard and delayed imaging. Results At least one lesion suggestive of recurrent or metastatic prostate cancer was identified on PET images in 52 patients (52.5%). Detection rates of [ 68 Ga]THP-PSMA PET/CT increased with increasing PSA level: 94.1% for a PSA value of ≥10 ng/mL, 77.3% for a PSA value of 2 to &lt;10 ng/mL, 54.5% for a PSA value of 1 to &lt;2 ng/mL, 14.3% for a PSA value of 0.5 to &lt;1 ng/mL, 20.0% for a PSA value of &gt;0.2 to &lt;0.5, and 22.2% for a PSA value of 0.01 to 0.2 ng/mL. [ 68 Ga]THP-PSMA uptake (SUVs) in metastases decreased over time, whereas TBRs improved. Delayed imaging at 3 h p.i. exclusively identified pathologic findings in 2% of [ 68 Ga]THP-PSMA PET/CT scans. Detection rate was higher in patients with a Gleason score ≥8 ( P =0.02) and in patients receiving androgen deprivation therapy ( P =0.003). Conclusions In this study, [ 68 Ga]THP-PSMA PET/CT showed suitable detection rates in patients with biochemical recurrence of prostate cancer and PSA levels ≥ 2 ng /mL. Detections rates were lower than in previous studies evaluating other PSMA ligands, though prospective direct radiotracer comparison studies are mandatory particularly in patients with low PSA levels to evaluate the relative performance of different PSMA ligands.</description><subject>Biochemistry</subject><subject>Cancer surgery</subject><subject>Cardiology</subject><subject>Chelation</subject><subject>Computed tomography</subject><subject>Deprivation</subject><subject>Elution</subject><subject>Image detection</subject><subject>Imaging</subject><subject>Ligands</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Metastases</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Patients</subject><subject>pH effects</subject><subject>Pharmaceuticals</subject><subject>Positron emission</subject><subject>Prostate cancer</subject><subject>Prostatectomy</subject><subject>Radiochemical analysis</subject><subject>Radioisotopes</subject><subject>Radiolabelling</subject><subject>Radiology</subject><subject>Therapy</subject><subject>Tomography</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kV9rFDEUxQdRsLZ-AN8u-OJDo8nsTDJ5XEr_CBUXun0qMmSSm93U2cyaZJV-QL-Xd7tFpOBT_vA799zDqap3gn8UnKtPmfO61YwLxWa6bph-UR0JKTRTvNMv_94Vf129yfmec9HVnT6qfi9u5iyXZErwAR04LGhLmCLQF2bwU4I72V2ab8urBVvcfJmfgoE4_cQRtmka8JFIZhscfA-FDSbTlL2AjWbAMcQVmOhgcb6EsDErep9CiLAlQ4wlw69Q1jCEya5xE6wZIaHdpYTRIhhfMJENCdMDlDWSz8OjIVnnQguCNQSmk-qVN2PGt0_ncXV7cb48u2LXXy8_n82vmRW60YwiO6mEtK1zs3pouFKKc42dxNZ5g0MrPdaDwc7UUnvnfcMbJ_ngGyNmQz07rj4c5pL_jx3m0m9CtjiOJuK0y73QnW4bLaQi9P0z9H7apUjb7am2VbJtJFHiQFkKlBP6_iltL3i_L7Y_FNtTsf2-2F6Tpj5oMrFxhemfyf8V_QFaT6fR</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Derlin, Thorsten</creator><creator>Schmuck, Sebastian</creator><creator>Juhl, Cathleen</creator><creator>Zörgiebel, Johanna</creator><creator>Schneefeld, Sophie M.</creator><creator>Walte, Almut C. A.</creator><creator>Hueper, Katja</creator><creator>von Klot, Christoph A.</creator><creator>Henkenberens, Christoph</creator><creator>Christiansen, Hans</creator><creator>Thackeray, James T.</creator><creator>Ross, Tobias L.</creator><creator>Bengel, Frank M.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8786-4105</orcidid></search><sort><creationdate>20180601</creationdate><title>PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer</title><author>Derlin, Thorsten ; Schmuck, Sebastian ; Juhl, Cathleen ; Zörgiebel, Johanna ; Schneefeld, Sophie M. ; Walte, Almut C. A. ; Hueper, Katja ; von Klot, Christoph A. ; Henkenberens, Christoph ; Christiansen, Hans ; Thackeray, James T. ; Ross, Tobias L. ; Bengel, Frank M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1949-828d6716c5dd32b40777009e86e5dfaeb56fe2bae8a269fdff404d60bf4a13b23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Biochemistry</topic><topic>Cancer surgery</topic><topic>Cardiology</topic><topic>Chelation</topic><topic>Computed tomography</topic><topic>Deprivation</topic><topic>Elution</topic><topic>Image detection</topic><topic>Imaging</topic><topic>Ligands</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Metastases</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Patients</topic><topic>pH effects</topic><topic>Pharmaceuticals</topic><topic>Positron emission</topic><topic>Prostate cancer</topic><topic>Prostatectomy</topic><topic>Radiochemical analysis</topic><topic>Radioisotopes</topic><topic>Radiolabelling</topic><topic>Radiology</topic><topic>Therapy</topic><topic>Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Derlin, Thorsten</creatorcontrib><creatorcontrib>Schmuck, Sebastian</creatorcontrib><creatorcontrib>Juhl, Cathleen</creatorcontrib><creatorcontrib>Zörgiebel, Johanna</creatorcontrib><creatorcontrib>Schneefeld, Sophie M.</creatorcontrib><creatorcontrib>Walte, Almut C. A.</creatorcontrib><creatorcontrib>Hueper, Katja</creatorcontrib><creatorcontrib>von Klot, Christoph A.</creatorcontrib><creatorcontrib>Henkenberens, Christoph</creatorcontrib><creatorcontrib>Christiansen, Hans</creatorcontrib><creatorcontrib>Thackeray, James T.</creatorcontrib><creatorcontrib>Ross, Tobias L.</creatorcontrib><creatorcontrib>Bengel, Frank M.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Database‎ (1962 - current)</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest advanced technologies &amp; aerospace journals</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Derlin, Thorsten</au><au>Schmuck, Sebastian</au><au>Juhl, Cathleen</au><au>Zörgiebel, Johanna</au><au>Schneefeld, Sophie M.</au><au>Walte, Almut C. A.</au><au>Hueper, Katja</au><au>von Klot, Christoph A.</au><au>Henkenberens, Christoph</au><au>Christiansen, Hans</au><au>Thackeray, James T.</au><au>Ross, Tobias L.</au><au>Bengel, Frank M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><date>2018-06-01</date><risdate>2018</risdate><volume>45</volume><issue>6</issue><spage>913</spage><epage>922</epage><pages>913-922</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Purpose [ 68 Ga]Tris(hydroxypyridinone)(THP)-PSMA is a novel radiopharmaceutical for one-step kit-based radiolabelling, based on direct chelation of 68 Ga 3+ at low concentration, room temperature and over a wide pH range, using direct elution from a 68 Ge/ 68 Ga-generator. We evaluated the clinical detection rates of [ 68 Ga]THP-PSMA PET/CT in patients with biochemically recurrent prostate cancer after prostatectomy. Methods Consecutive patients (n=99) referred for evaluation of biochemical relapse of prostate cancer by [ 68 Ga]THP-PSMA PET/CT were analyzed retrospectively. Patients underwent a standard whole-body PET/CT (1 h p.i.), followed by delayed (3 h p.i.) imaging of the abdomen. PSA-stratified cohorts of positive PET/CT results, standardized uptake values (SUVs) and target-to-background ratios (TBRs) were analyzed, and compared between standard and delayed imaging. Results At least one lesion suggestive of recurrent or metastatic prostate cancer was identified on PET images in 52 patients (52.5%). Detection rates of [ 68 Ga]THP-PSMA PET/CT increased with increasing PSA level: 94.1% for a PSA value of ≥10 ng/mL, 77.3% for a PSA value of 2 to &lt;10 ng/mL, 54.5% for a PSA value of 1 to &lt;2 ng/mL, 14.3% for a PSA value of 0.5 to &lt;1 ng/mL, 20.0% for a PSA value of &gt;0.2 to &lt;0.5, and 22.2% for a PSA value of 0.01 to 0.2 ng/mL. [ 68 Ga]THP-PSMA uptake (SUVs) in metastases decreased over time, whereas TBRs improved. Delayed imaging at 3 h p.i. exclusively identified pathologic findings in 2% of [ 68 Ga]THP-PSMA PET/CT scans. Detection rate was higher in patients with a Gleason score ≥8 ( P =0.02) and in patients receiving androgen deprivation therapy ( P =0.003). Conclusions In this study, [ 68 Ga]THP-PSMA PET/CT showed suitable detection rates in patients with biochemical recurrence of prostate cancer and PSA levels ≥ 2 ng /mL. Detections rates were lower than in previous studies evaluating other PSMA ligands, though prospective direct radiotracer comparison studies are mandatory particularly in patients with low PSA levels to evaluate the relative performance of different PSMA ligands.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><doi>10.1007/s00259-017-3924-9</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-8786-4105</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1619-7070
ispartof European journal of nuclear medicine and molecular imaging, 2018-06, Vol.45 (6), p.913-922
issn 1619-7070
1619-7089
language eng
recordid cdi_proquest_miscellaneous_1989549167
source Springer Nature
subjects Biochemistry
Cancer surgery
Cardiology
Chelation
Computed tomography
Deprivation
Elution
Image detection
Imaging
Ligands
Medicine
Medicine & Public Health
Metastases
Nuclear Medicine
Oncology
Original Article
Orthopedics
Patients
pH effects
Pharmaceuticals
Positron emission
Prostate cancer
Prostatectomy
Radiochemical analysis
Radioisotopes
Radiolabelling
Radiology
Therapy
Tomography
title PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T11%3A50%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PSA-stratified%20detection%20rates%20for%20%5B68Ga%5DTHP-PSMA,%20a%20novel%20probe%20for%20rapid%20kit-based%2068Ga-labeling%20and%20PET%20imaging,%20in%20patients%20with%20biochemical%20recurrence%20after%20primary%20therapy%20for%20prostate%20cancer&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Derlin,%20Thorsten&rft.date=2018-06-01&rft.volume=45&rft.issue=6&rft.spage=913&rft.epage=922&rft.pages=913-922&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-017-3924-9&rft_dat=%3Cproquest_cross%3E1989549167%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1949-828d6716c5dd32b40777009e86e5dfaeb56fe2bae8a269fdff404d60bf4a13b23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1985576546&rft_id=info:pmid/&rfr_iscdi=true